Linezolid versus Vancomycin for Prosthetic Joint Infections: a Cost Analysis

@article{You2007LinezolidVV,
  title={Linezolid versus Vancomycin for Prosthetic Joint Infections: a Cost Analysis},
  author={Joyce H S You and Grace Clara Lee and Ryuhei So and Kai Wing Cheung and Mamie Hui},
  journal={Infection},
  year={2007},
  volume={35},
  pages={265-270}
}
Prosthetic joint infections (PJIs) caused by methicillin-resistant gram-positive bacteria are primarily treated by intravenous vancomycin. Linezolid, active against methicillin-resistant strains and available in oral and intravenous dosage forms, is a potential alternative to vancomycin for the treatment of PJIs. To analyze the cost of linezolid therapy (outpatient setting) and vancomycin therapy (inpatient and outpatient settings) for PJIs caused by methicillin-resistant gram-positive bacteria… CONTINUE READING